Pharsight

Quviviq is owned by Idorsia.

Quviviq contains Daridorexant Hydrochloride.

Quviviq has a total of 3 drug patents out of which 0 drug patents have expired.

Quviviq was authorised for market use on 07 April, 2022.

Quviviq is available in tablet;oral dosage forms.

Quviviq can be used as treatment of insomnia.

Drug patent challenges can be filed against Quviviq from 2026-04-07.

The generics of Quviviq are possible to be released after 02 December, 2034.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732075	IDORSIA	Benzimidazole-proline derivatives	Jun, 2033 (10 years from now)
US9790208	IDORSIA	Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist	Dec, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560	IDORSIA	Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist	Dec, 2034 (11 years from now)